Insmed CEDAR Study Misses Endpoints in HS Trial
BRIDGEWATER, N.J., April 7, 2026 Insmed Incorporated has announced that its Phase 2b CEDAR clinical trial evaluating brensocatib in...
Hidradenitis Suppurativa
Advertisement
OSE Expands Lusvertikimab Into Pouchitis and HS
Nantes, France | January 29, 2026 — OSE Immunotherapeutics announced the strategic selection of chronic pouchitis and hidradenitis suppurativa...
InflaRx Secures INN “Izicopan” for Oral C5aR Inhibitor INF904
JENA, Germany, December 11, 2025 — InflaRx N.V. announced that the World Health Organization (WHO) has granted the International...
Celltrion Gains FDA Nod for YUFLYMA Pediatric Use Expansion
Incheon, South Korea – October 16, 2025 – CelltrionUSA, a subsidiary of Celltrion Inc., announced that the U.S. Food...
Advertisement
